Search
Delta-1-pyrroline-5-carboxylate synthase
go.drugbank.com/bio_entities/BE0000823TargetHumansBifunctional enzyme that converts glutamate to glutamate 5-semialdehyde, an intermediate in the biosynthesis of proline, ornithine and arginine
Polypeptides: Delta-1-pyrroline-5-carboxylate synthase5-aminolevulinate synthase, erythroid-specific, mitochondrial
go.drugbank.com/bio_entities/BE0000898TargetHumansCatalyzes the pyridoxal 5'-phosphate (PLP)-dependent condensation of succinyl-CoA and glycine to form aminolevulinic acid (ALA), with CoA and CO2 as by-products (PubMed:14643893, PubMed:21252495, PubMed
Polypeptides: 5-aminolevulinate synthase, erythroid-specific, mitochondrialSynonyms: 5-aminolevulinic acid synthase 23',5'-cyclic-AMP phosphodiesterase 4A
go.drugbank.com/bio_entities/BE0001133TargetHumansHydrolyzes the second messenger 3',5'-cyclic AMP (cAMP), which is a key regulator of many important physiological processes
Polypeptides: 3',5'-cyclic-AMP phosphodiesterase 4AFunction: 3',5'-cyclic-AMP phosphodiesterase activity3',5'-cyclic-AMP phosphodiesterase 4C
go.drugbank.com/bio_entities/BE0002353TargetHumansHydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes
Polypeptides: 3',5'-cyclic-AMP phosphodiesterase 4CFunction: 3',5'-cyclic-AMP phosphodiesterase activityBaculoviral IAP repeat-containing protein 5
go.drugbank.com/bio_entities/BE0003408TargetHumansMultitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis (PubMed:20627126, PubMed:21364656, PubMed:25778398, PubMed:28218735, PubMed:9859993). Component of a chromosome passage protein complex (CP...
Polypeptides: Baculoviral IAP repeat-containing protein 5Serine/threonine-protein kinase PAK 5
go.drugbank.com/bio_entities/BE0009510TargetHumansSerine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, proliferation or cell survival. Activation by various effectors including growth factor rec...
Polypeptides: Serine/threonine-protein kinase PAK 5Synonyms: PAK-5, p21-activated kinase 5Sitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalSitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256 … The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255].
Mixtures: JANUMET 50 MG/500 MG FILM KAPLI TABLET, 56 ADET, JANUMET 50 MG/850 MG FILM KAPLI TABLET, 56 ADETCategories: Drugs Used in Diabetes, Cytochrome P-450 SubstratesNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459] … first-line treatment following diagnosis to slow down the progressive loss of lung function.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylateFingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalMultiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. … It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesProducts: FINGOLIMOD EG, LEBRINA® 0.5 MGDesmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalIt is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone [A275458, L56105 … On January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery
Synonyms: 1 deamino 8 D argininevasopressin, 1-(3-mercaptopropionic acid)-8-D-arginine-vasopressinProducts: DESMOPRESIN®0.2 MG, DESMOVITAL %0,1 MG/ML BURUN SPREYI, 6 ML